Press Release: RetInSight Announces Exclusive Distribution Agreement with Kilabs Srl for the Italian Market
Vienna – February 25, 2025 – RetInSight GmbH, a leading developer of AI-powered and MDR-certified medical software solutions for retinal diseases, has entered into an exclusive distribution agreement with Kilabs Srl for the Italian market. This collaboration will expand access to RetInSight’s clinically validated AI solutions, supporting ophthalmologists in the diagnosis and management of age-related macular degeneration (AMD).
02/2025
Vienna – February 25, 2025 – RetInSight GmbH, a leading developer of AI-powered and MDR-certified medical software solutions for retinal diseases, has entered into an exclusive distribution agreement with Kilabs Srl for the Italian market. This collaboration will expand access to RetInSight’s clinically validated AI solutions, supporting ophthalmologists in the diagnosis and management of age-related macular degeneration (AMD).
Effective immediately, Kilabs has exclusive rights to distribute Fluid Monitor and GA Monitor in Italy. Both AI-based software solutions are MDR-certified for use in routine clinical practice, ensuring compliance with the highest European regulatory standards. Notably, GA Monitor is the first and only MDR-certified software currently available for the diagnosis and monitoring of geographic atrophy (GA) in a clinical setting.
"We are pleased to partner with Kilabs to bring our AI-powered solutions to ophthalmologists and healthcare providers across Italy", says Corinna zur Bonsen-Thomas, CEO of RetInSight. "This agreement reflects our commitment to advancing retinal disease management through clinically validated, accessible, and efficient AI technology."
"I am really very proud to be involved in such a prestigious program to monitor maculopathy and retinopathy at an early stage. Italian ophthalmologists will be supported in their decision making, bringing added value to patients and sustainability”, says Michelangelo Simonelli, CEO of Kilabs.
RetInSight’s software solutions are designed to enhance clinical decision-making by providing automated, objective assessments of retinal disease progression, with the Fluid Monitor being used for patients with exudative neovascular AMD (nAMD), while the GA Monitor is intended for patients with geographic atrophy (GA).
Both solutions generate a clear, easy-to-interpret PDF report within minutes, assisting ophthalmologists in diagnosing, monitoring, and managing AMD more effectively. By integrating AI-driven analysis into routine practice, these tools support timely and personalized treatment decisions, ultimately improving patient care.
Through this partnership, RetInSight and Kilabs aim to provide Italian ophthalmologists with cutting-edge AI technology that enhances clinical workflows and improves outcomes for patients at risk of vision loss.
About the RetInSight Fluid Monitor
The RetInSight Fluid Monitor is an AI-based software for the precise and automatic evaluation of OCT images in clinical routine. It allows doctors to instantly recognize and quantify disease-specific fluids in various retinal layers. These fluid accumulations are key indicators of the activity of neovascular age-related macular degeneration (nAMD, wet AMD). The Fluid Monitor provides a clear and visualized PDF report, offering a practical and high-quality basis for assessing disease progression and tailoring treatment for optimal outcomes.
About the RetInSight GA Monitor
The RetInSight GA Monitor is an AI-based software for the interpretation of OCT images as part of the management of geographic atrophy (GA), the dry form of AMD.
This disease leads to severe, irreversible vision loss. The GA Monitor visualizes, localizes and quantifies the degeneration of the photoreceptors (PR) and the loss of the retinal pigment epithelium (RPE) in the retina long before this is recognizable in clinical routine. Within minutes, it creates a clear, one-page PDF report that is available to the ophthalmologist at the click of a mouse.
The software thus enables, for the first time, a comprehensive and early recording of the activity and stage of GA, which was previously not possible for the ophthalmologist using routine methods. In addition, the report’s easy-to-understand images support patient communication in this serious chronic disease.
About Kilabs
Kilabs Srl was founded in 2019 by a group of highly experienced leaders in ophthalmology. The company brings international excellence to Italy, fosters research, and develops new products for specialized pathologies in collaboration with Italian universities.
Kilabs' mission is to research, develop, and share innovative solutions to diagnose, manage, and treat patients in specialty areas – enhancing their quality of life.
About RetInSight
RetInSight GmbH, based in Vienna, was founded in 2020 with the ambition that longevity should not come at the expense of vision loss. We aim to enable people to maintain their full vision in order to preserve their quality of life and lifelong autonomy. We are therefore developing transformative AI-based software solutions that leverage routine optical coherence tomography (OCT) images to monitor and detect progressive retinal diseases such as geographic atrophy (GA), neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) – the most important age-related diseases that lead to visual impairments in today’s world. Our mission is to revolutionize ophthalmology through reliable, affordable, and easy-to-use AI-based medical software that enables timely diagnosis, accurate monitoring, and personalized treatment of retinal diseases for anyone, any time and at any location by supporting networked care in ophthalmology with the help of AI technology and digital data.
Contact Kilabs
KILABS srl
Michelangelo Simonelli, CEO
Via Zoe Fontana, 220 Unità 2B CAP 00131
Roma, Italy
E-Mail: info@kilabspharma.it
Media Contact RetInSight
RetInSight GmbH
Klaudia Schuh, Head of Marketing & Communications
Tel: +43 677 610 749 47
E-Mail: klaudia.schuh@retinsight.com
www.retinsight.com